Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.
The expression of various chromogranin A (CgA) peptide fragments was examined with region-specific antisera in benign and malignant pituitary tumors. Analysis of the proconvertases responsible for proteolytic processing of CgA, prohormone convertase 1/3 (PC1/3), and PC2 was also performed. Adenomas were studied using tissue microarrays, and a larger tissue section of a subset of the prolactin (PRL) adenomas was used to compare to the tissue microarray analysis. Carcinomas were analyzed using larger tissue sections. There were differences in CgA proteolytic products detected between the functional (PRL, adrenocorticotropic hormone [ACTH], and growth hormone tumors and the nonfunctional (gonadotroph and null cell) tumors, with the former group expressing lower levels of many peptides. These differences were most notable in the PRL adenomas and carcinomas in which the region-specific antisera against vasostatin I and vasostatin II detected these fragments in the lowest percentage of tumors and/or had the weakest immunoreactivity. The CgA peptide fragment detected by CgA 176-195 (chromacin) antiserum was expressed by the highest percentage of most functional and nonfunctional benign and malignant pituitary tumors. ACTH carcinomas (n = 3) were more strongly immunoreactive compared to the ACTH adenomas. These results show that there is differential expression of CgA peptide fragments and PC1/3 among different types of pituitary tumors and that ACTH pituitary carcinomas have higher levels of immunoreactive CgA peptide fragments compared to ACTH adenomas. This study also shows the utility of tissue microarrays in the analysis of a large group of tumors with regionspecific antisera.
Jin
Long
L
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Zhang
Shuya
S
Bayliss
Jill
J
Scheithauer
Bernd
B
Qian
Xiang
X
Kobayashi
Ikuo
I
Stridsberg
Mats
M
Lloyd
Ricardo V
RV
D000236:Adenoma / Q000276:immunology / Q000378:metabolism*; D016282:Aspartic Acid Endopeptidases / Q000276:immunology / Q000378:metabolism; D015153:Blotting, Western; D002277:Carcinoma / Q000276:immunology / Q000378:metabolism*; D053379:Chromogranin A; D002864:Chromogranins / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D010911:Pituitary Neoplasms / Q000276:immunology / Q000378:metabolism*; D045706:Proprotein Convertase 2; D043484:Proprotein Convertases; D013381:Subtilisins / Q000276:immunology / Q000378:metabolism; D014407:Tumor Cells, Cultured
C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D043484:Proprotein Convertases; D013381:Subtilisins; D045706:Proprotein Convertase 2; D016282:Aspartic Acid Endopeptidases